乳腺癌中胰岛素样生长因子信号途径及其抑制剂研究  

IGF pathway and its inhibitor for breast cancer

作　　者：胡晨[1] 陈彬[2] 王越[2] 陈先华[3] 

机构地区：[1]第三军医大学学员旅8队,重庆400038 [2]第三军医大学生物化学与分子生物学教研室,重庆400038 [3]第三军医大学西南医院保健科,重庆400038

出　　处：《生命的化学》2009年第6期907-912,共6页Chemistry of Life

基　　金：国家自然科学基金(No.30972933);重庆市自然科学基金(No.2009AC5173)资助

摘　　要：胰岛素样生长因子(insulin-like growth factor,IGF)信号途径不仅在乳腺的正常发育中起到一定作用,也调节了乳腺癌的增生、存活及转移。因此IGF信号途径的抑制已逐渐成为乳腺癌治疗的一个重要靶点。另外,该途径能与人体内其他信号途径串话并在引发内分泌治疗抵抗或赫赛汀(herceptin)治疗抵抗方面起重要作用。因此,IGF途径抑制剂与其他信号途径抑制剂联合用药在治疗乳腺癌,特别是伴随有内分泌治疗抵抗或赫赛汀治疗抵抗的乳腺癌方面的运用越来越广泛。本文对乳腺癌中IGF信号途径及其抑制剂的研究进展进行了综述。IGF pathway not only plays a role in the normal development of the mammary gland, but also regulates proliferation, survival and metastasis of breast cancer. So the inhibition of IGF signaling has become an increasingly important target for cancer including breast cancer therapy. On the other hand, IGF pathway can also cross-talk with other pathways and play an important role in cause of endocrine resistance or herceptin resistance. So potential combination strategies of IGF inhibitors and other pathway inhibitors are used more and more for the therapy of breast cancer, special breast cancer accompanying the endocrine resistance or herceptin resistance. In this review, the recent research progress of IGF pathway and its inhibitors is discussed.

关 键 词：胰岛素样生长因子 抑制剂 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]